|Description||GSK-356278 is a selective Type 4 cyclic nucleotide phosphodiesterase inhibitor. It shows anxiolytic and cognition-enhancing effects and it has the ability to elevate cAMP in various cell types of the central nervous system. No development was reported for phase-I development in Major depressive disorder and Huntington's-disease.|
|Solubility||Soluble in DMSO|
|Application||Huntington's disease; Major depressive disorder|
|Quality Standard||In-house standard|
|Shelf Life||2 month in rt, long time|
|Current Developer||Originator GlaxoSmithKline|
ICI 63197 is a specific and potent cAMP phosphodiesterase IV (PDE 4) inhibitor. Its IC50 value is 35 nM for inhibition of [3H]-rolipram binding to rat brain. It...
Ronomilast is type 4 cyclic nucleotide phosphodiesterase inhibitor for the treatment of chronic obstructive pulmonary disease (COPD).
YM 976 is an orally bioactive PDE4 inhibitor (IC50 = 2.2 nM). YM 976 inhibits PDE4 to maintain cAMP and prolong signal transduction.
MK0873 is a phosphodiesterase 4 (PDE4) inhibitor. It has shown as an innovative tool to design topical formulation to achieve desired pharmacokinetics in humans...
Selective phosphodiesterase 4 (PDE4) inhibitor. Antiasthmatic; used in treatment of chronic obstructive pulmonary disease.
CP-671305 is a potent and selective inhibitor of PDE4.
AN3199, a PDE4 inhibitor, was once studied as an anti-inflammatory agent. IC50: 94.5 nM
S-(+)-Rolipram inhibits human monocyte cyclic AMP-specific PDE4 with IC50 of 0.75 μM, has anti-inflammatory and anti-depressant activity in the central nervous ...
BAY 19-8004 is a selective inhibitor of phosphodiesterase-4 (PDE4) used for the treatment of COPD.
MK-0359 is a selective and potent oral PDE4 inhibitor with in vivoefficacy in animal models of asthma and cognition.
GSK-356278 is a selective Type 4 cyclic nucleotide phosphodiesterase inhibitor. It shows anxiolytic and cognition-enhancing effects and it has the ability to el...
CI-1044, a selective PDE4 inhibitor, inhibits in vitro LPS-induced TNF-alpha release in whole blood from COPD patients better than rolipram and cilomilast and s...
Roflumilast has antiinflammatory effects and is under development as an orally administered drug for the treatment of inflammatory conditions of the lungs such ...
NVP-ABE171 is a potent and novel phosphodiesterase 4 inhibitor with anti-inflammatory activities inhibited the activity of phosphodiesterase 4A, 4B, 4C, and 4D ...
CP 80633 is an inhibitor of phosphodiesterase type 4 and exhibit anti-inflammatory and bronchodilatory effects in vivo.
Etazolate hydrochloride is a phosphodiesterase inhibitor with selectivity for PDE4 (IC50 = 2.0 μM).
GSK256066 is a selective PDE4B(equal affinity to isoforms A-D) inhibitor with IC50 of 3.2 pM, >380,000-fold selectivity versus PDE1/2/3/5/6 and >2500-fold selec...
CP-220629, a Pyrazolopyridin derivative, has been found to be a Type 4 cyclic nucleotide phosphodiesterase inhibitor that was once studied as an anti-inflammato...
L-869298 is a high potent and selective PDE4 inhibitor, acts as a Type 4 cyclic nucleotide phosphodiesterase inhibitor.
Eggmanone is a potent and selective phosphodiesterase (PDE) 4 inhibitor (IC50 = 72 nM) displaying >40-fold selectivity over PDE3, PDE10, and PDE11. Eggmanone ac...